Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

11.40EUR
1 Oct 2014
Price Change (% chg)

€-0.22 (-1.89%)
Prev Close
€11.62
Open
€11.52
Day's High
€11.63
Day's Low
€11.28
Volume
27,351
Avg. Vol
238,670
52-wk High
€13.03
52-wk Low
€9.38

ALM.MC

Chart for ALM.MC

About

Almirall SA is a Spain-based company principally engaged in the research, development, storage and distribution of pharmaceutical products. The Company’s range of products include a variety of drugs for the treatment of diseases in such therapeutic areas as asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal... (more)

Overall

Beta: 0.54
Market Cap (Mil.): €2,020.07
Shares Outstanding (Mil.): 172.95
Dividend: 0.15
Yield (%): 1.31

Financials

  ALM.MC Industry Sector
P/E (TTM): -- 33.26 33.98
EPS (TTM): -0.19 -- --
ROI: -2.60 18.14 17.39
ROE: -3.63 18.84 18.24
Search Stocks

EU agency backs Almirall lung drug being bought by AstraZeneca

LONDON - A combination drug for chronic lung disease from Spain's Almirall, one of a number of respiratory medicines being acquired by AstraZeneca, has been recommended for approval by European regulators.

25 Sep 2014

EU agency backs Almirall lung drug being bought by AstraZeneca

LONDON, Sept 25 - A combination drug for chronic lung disease from Spain's Almirall, one of a number of respiratory medicines being acquired by AstraZeneca, has been recommended for approval by European regulators.

25 Sep 2014

Almirall says in deal with Astrazeneca over respiratory business

MADRID, July 30 - Spain's Almirall on Wednesday said it had reached a deal to transfer to Astrazeneca the rights of its respiratory franchise for an initial $875 million. (Reporting by Julien Toyer; Editing by Tracy Rucinski)

30 Jul 2014

AstraZeneca boosts lung drug business with up to $2.1 bln Almirall deal

LONDON, July 30 - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

30 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks